N4P — N4 Pharma Income Statement
0.000.00%
Last trade - 00:00
- £2.28m
- £0.99m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.073 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1.49 | 0.947 | 1.56 | 1.84 | 1.19 |
Operating Profit | -1.42 | -0.947 | -1.56 | -1.84 | -1.19 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -1.39 | -0.949 | -1.57 | -1.84 | -1.19 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.18 | -0.876 | -1.3 | -1.54 | -1.03 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.18 | -0.876 | -1.3 | -1.54 | -1.03 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.18 | -0.876 | -1.3 | -1.54 | -1.03 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.013 | -0.009 | -0.01 | -0.009 | -0.006 |